TF
ALNY icon

Theory Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Theory Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$908K Hold
2,744
– – 0.32% 59
2025
Q4 		$992K Buy
+2,744
New +$1.21M 0.33% 57

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theory Financial's ALNY Position: Q1 2026 in Review

Theory Financial held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 2,744 shares worth $908K. The position accounts for 0.32% of the portfolio, ranked #59.

Theory Financial first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. The position peaked at $992K in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Theory Financial held 2,744 shares of Alnylam Pharmaceuticals worth $908K as of Q1 2026.
  • Theory Financial left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.32% of Theory Financial's portfolio in Q1 2026, its #59 holding.
  • Theory Financial first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Theory Financial's Alnylam Pharmaceuticals position peaked at $992K in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Theory Financial's 13F filing for Q1 2026, filed 5 May 2026.